- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | The Subscription Period in Spago Nanomedical's Rights Issue Begins Today | 224 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 06.11. | Spago Nanomedical AB: Spago Nanomedical publishes information document in connection with forthcoming rights issue | 96 | GlobeNewswire (Europe) | The board of directors of Spago Nanomedical AB (publ) ("Spago Nanomedical" or "the Company") has today published an information document in connection with the Company's new share issue with rights... ► Artikel lesen | |
| 03.11. | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.11.2025 | 239 | Xetra Newsboard | Das Instrument GW3 SE0009155518 GAPWAVES AB CLASS B O.N. EQUITY wird cum Kapitalmassnahme gehandelt am 03.11.2025 und ex Kapitalmassnahme am 04.11.2025 The instrument GW3 SE0009155518 GAPWAVES AB CLASS... ► Artikel lesen | |
| 29.10. | Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 25 million to Advance Tumorad | 192 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 29.10. | Spago Nanomedical Interim Report January-September 2025 | 209 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 29, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)JULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 14 (KSEK 485)The loss for the quarter amounted... ► Artikel lesen | |
| 14.10. | Visible Tumor Uptake and Recommended Dose Increase in Spago Nanomedicals's Phase I/IIa Study Tumorad-01 | 172 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 14, 2025 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends a dose increase... ► Artikel lesen | |
| 20.08. | Spago Nanomedical Interim Report January-June, 2025 | 271 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)APRIL - JUNE IN BRIEFNet sales for the quarter amounted to KSEK 81 (KSEK 459)The loss for the quarter amounted... ► Artikel lesen | |
| SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 03.06. | Spago Nanomedical Continues Patient Recruitment in the Phase I/IIa Study Tumorad-01 as Planned after DMC Recommendation | 273 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 3, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the Data Monitoring Committee (DMC) recommends the ongoing... ► Artikel lesen | |
| 14.05. | Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB | 306 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 14, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, May 14, 2025, at which the AGM... ► Artikel lesen | |
| 07.05. | Spago Nanomedical Interim Report January-March, 2025 | 332 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 7, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 338 (KSEK 350)The loss for the quarter amounted... ► Artikel lesen | |
| 15.04. | Spago Nanomedical Publishes The Annual Report for 2024 | 334 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2024 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen | |
| 09.04. | Notice To Annual General Meeting of Spago Nanomedical AB | 348 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 9, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version... ► Artikel lesen | |
| 20.03. | Nomination Committee's Proposal for a New Chairman and Composition of Spago Nanomedical's Board | 657 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company's nomination committee proposes a changed board... ► Artikel lesen | |
| 04.03. | Spago Nanomedical Proceeds with Increased Dose in the Phase I/IIa study Tumorad-01 | 376 | ACCESS Newswire | LUND, SE / ACCESSWIRE / March 04, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends a dose... ► Artikel lesen | |
| 06.02. | Spago Nanomedical year-end report January-December, 2024 | 297 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 6, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 617 (KSEK 731)The loss for the quarter... ► Artikel lesen | |
| 15.01. | Spago Nanomedical Article on SPAGOPIX-01 Clinical Results Accepted for Publication in Investigative Radiology | 266 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / January 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that a manuscript on product candidate pegfosimer manganese has... ► Artikel lesen | |
| 18.12.24 | Second Patient Group Successfully Dosed in Spago Nanomedical's Phase I/IIa Study Tumorad-01 | 475 | ACCESS Newswire | LUND, SE / ACCESSWIRE / December 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that all patients in the second patient group have been dosed according... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| COGENT BIOSCIENCES | 33,540 | -0,80 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 40,850 | -7,77 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| QIAGEN | 38,165 | -1,37 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen anlässlich der jüngst präsentierten Quartalszahlen von 50 auf 46 Euro gesenkt, die Einstufung aber auf "Buy" belassen.... ► Artikel lesen | |
| EVOTEC | 5,290 | -2,97 % | Evotec unter Druck | Die Evotec-Aktie steht nach einem heftigen Rückschlag erneut unter Beobachtung. Kann sich der Biotech-Wert bei 5 EUR stabilisieren Den vollständigen Artikel lesen ... ► Artikel lesen | |
| BIONTECH | 88,65 | -0,06 % | BioNTech, Hensoldt, Börse München, ICF BANK - 4investors-Weekend | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Und welche DAX-Titel haben besonders starke Kursbewegungen verzeichnet? Vor allem für Trader ist es wichtig zu... ► Artikel lesen | |
| NUVALENT | 96,50 | +2,05 % | Nuvalent kündigt Präsentation zulassungsrelevanter Daten für Lungenkrebs-Wirkstoff an | ||
| AVIDITY BIOSCIENCES | 70,80 | -0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| INVIVYD | 2,345 | +32,49 % | Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights | PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarterOctober 2025 ending cash and cash equivalents... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,135 | -4,50 % | Change at the top of Recursion as co-founder leaves CEO role | ||
| ARCUTIS BIOTHERAPEUTICS | 25,070 | +9,67 % | Arcutis completes enrollment in infant atopic dermatitis study | ||
| KYMERA THERAPEUTICS | 64,94 | +2,21 % | Kymera Therapeutics: Stifel bekräftigt "Buy"-Rating im Vorfeld entscheidender Daten | ||
| PRAXIS PRECISION MEDICINES | 186,07 | +4,49 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 22,770 | +11,56 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| VERA THERAPEUTICS | 28,350 | -0,07 % | Vera Therapeutics stock price target raised to $90 from $85 at H.C. Wainwright | ||
| STRUCTURE THERAPEUTICS | 36,810 | +5,17 % | Structure Therapeutics stock holds Outperform rating at BMO ahead of key data |
SPAGO NANOMEDICAL AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,002 (+25,71 %) liegt der Kurs bei 0,009 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.